Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10493459" target="_blank" >RIV/00179906:_____/25:10493459 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/26:00564320 RIV/00843989:_____/25:E0111776 RIV/00216224:14110/25:00141734 RIV/61988987:17110/25:A2603DO9 a 6 dalších

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=svoq~BeJgo" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=svoq~BeJgo</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2024.287062" target="_blank" >10.3324/haematol.2024.287062</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Popis výsledku v původním jazyce

Blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, is effective in treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL), though most patients relapse despite achieving measurable residual disease (MRD) negativity. In the MRD setting, blinatumomab induced MRD negativity (MRDneg) in 78% of patients, with 85% achieving MRD &lt;10-4. Patients treated in their first complete remission (CR) showed better outcomes than those treated in later remissions. These findings support integrating blinatumomab into first-line polychemotherapy, as early MRD clearance significantly improves survival and reduces relapse risks.3 The open-label phase 2 Blina-CELL trial evaluated the effects of one cycle of blinatumomab following 7-day pretreatment with dexamethasone and chemotherapy in adult patients with Ph-negative B-ALL. Conducted at four centers in the Czech Republic, the trial assessed MRDneg rates after a short Pre- Induction, one cycle of blinatumomab and one cycle of high-dose chemotherapy. The study was approved by central and institutional review boards and registered on clinicaltrials.gov (NCT04554485). All participants provided informed consent in accordance with the Declaration of Helsinki.

Název v anglickém jazyce

Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia

Popis výsledku anglicky

Blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, is effective in treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL), though most patients relapse despite achieving measurable residual disease (MRD) negativity. In the MRD setting, blinatumomab induced MRD negativity (MRDneg) in 78% of patients, with 85% achieving MRD &lt;10-4. Patients treated in their first complete remission (CR) showed better outcomes than those treated in later remissions. These findings support integrating blinatumomab into first-line polychemotherapy, as early MRD clearance significantly improves survival and reduces relapse risks.3 The open-label phase 2 Blina-CELL trial evaluated the effects of one cycle of blinatumomab following 7-day pretreatment with dexamethasone and chemotherapy in adult patients with Ph-negative B-ALL. Conducted at four centers in the Czech Republic, the trial assessed MRDneg rates after a short Pre- Induction, one cycle of blinatumomab and one cycle of high-dose chemotherapy. The study was approved by central and institutional review boards and registered on clinicaltrials.gov (NCT04554485). All participants provided informed consent in accordance with the Declaration of Helsinki.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

1592-8721

Svazek periodika

110

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

5

Strana od-do

1644-1648

Kód UT WoS článku

001524687800023

EID výsledku v databázi Scopus

2-s2.0-105009547616